Takara Bio Report

Overview

The report presents Takara Bio's FY2020 consolidated performance, including net sales of ¥34,565 million and operating income of ¥6,274 million. It highlights the company's COVID-19 response through PCR-test reagent and kit activities and collaboration on vaccine development. It also introduces the Takara Group Sustainability Policy, a ten-issue materiality matrix, and environmental and social disclosures.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: Ends 31 March 2020
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services